This trial is studying niraparib as a possible treatment for prostate cancer. It is testing how well it works with standard treatments of radiation and hormonal therapy, and what the side effects are.
1 Primary · 7 Secondary · Reporting Duration: Up to 3 years
Active Control
Experimental Treatment
180 Total Participants · 3 Treatment Groups
Primary Treatment: Niraparib · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: